4.6 Article

Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology

Journal

FRONTIERS IN NEUROSCIENCE
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2017.00053

Keywords

Lewy body diseases; narrative comprehension; frontal lobe; cerebrospinal fluid; amyloid; tau

Categories

Funding

  1. National Institutes of Health [NS053488, AG038490, AG017586, NS043503, NS088341]

Ask authors/readers for more resources

Background: DEJ7Zay-to-day interactions depend on conversational narrative, and we examine here the neurobiological basis for difficulty organizing narrative discourse in patients with Lewy body disorders (LBD). Method: Narrative organization was examined in 56 non-aphasic LBD patients, including a non-demented cohort (n = 30) with Parkinson's disease (PD) or PD-Mild Cognitive Impairment PD-MCI,) and a cohort with mild dementia (n = 26) including PD-dementia (PDD) and dementia with Lewy bodies (DLB), with similar age and education but differing in MMSE (p < 0.001). We used a previously reported procedure that probes patients' judgments of the organization of brief, familiar narratives (e.g., going fishing, wrapping a present). A subgroup of 24 patients had MRI assessment of regional gray matter (GM) atrophy and cerebrospinal fluid (CSF) levels of biomarkers for Alzheimer's disease (AD) pathology, including beta amyloid (A), total-tau (t-tau), and phosphorylated-tau (p-tau). Results: Mildly demented LBD patients had a significant deficit judging narratives compared to non-demented patients, but this deficit was not correlated with MMSE. Regression analyses instead related narrative organization to regions of frontal GM atrophy, and CSF levels of A and t-tau associated with presumed AD pathology in these frontal regions. Conclusion: These findings are consistent with the hypothesis that CSF markers of AD pathology associated with frontal regions play a role in difficulty organizing narratives in LBD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Geriatrics & Gerontology

Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's disease

Benjamin J. Kim, Murray Grossman, Tomas S. Aleman, Delu Song, Katheryn A. Q. Cousins, Corey T. McMillan, Adrienne Saludades, Yinxi Yu, Edward B. Lee, David Wolk, Vivianna M. Van Deerlin, Leslie M. Shaw, Gui-Shuang Ying, David J. Irwin

Summary: Photoreceptor outer nuclear layer (ONL) thinning can distinguish frontotemporal lobar degeneration tauopathy (FTLD-Tau) from Alzheimer's disease (AD) and correlates with disease severity in FTLD-Tau.

NEUROBIOLOGY OF AGING (2023)

Article Clinical Neurology

Plasma phosphorylated tau181 predicts cognitive and functional decline

Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw

Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.

BRAIN (2023)

Article Clinical Neurology

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis

Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.

NEUROTHERAPEUTICS (2023)

Review Clinical Neurology

Fluid and Biopsy Based Biomarkers in Parkinson's Disease

David G. Coughlin, David J. Irwin

Summary: Several advances have been made in fluid and tissue-based biomarkers for Parkinson's disease (PD) and other synucleinopathies in the last few years. Immunohistochemistry, immunofluorescence, and alpha-synuclein seeding amplification assays now offer a crucial advancement in identifying different species of alpha-synuclein in PD patients. Co-pathology of Alzheimer's disease (AD) is commonly found in PD and dementia with Lewy bodies (DLB), and biofluid biomarkers for tau and amyloid beta species can detect this co-pathology.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Neurosciences

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

Kalpana M. Merchant, Tanya Simuni, Janel Fedler, Chelsea Caspell-Garcia, Michael Brumm, Kelly N. H. Nudelman, Elizabeth Tengstrandt, Frank Hsieh, Roy N. Alcalay, Christopher Coffey, Lana Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline Tanner, Ken Marek

Summary: We quantified concentrations of three isoforms of BMP in different cohorts of Parkinson's disease patients and found that LRRK2 and GBA1 gene mutations were associated with elevated BMP levels. However, BMP is not a prognostic or disease progression biomarker.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Temporal course of cognitive and behavioural changes in motor neuron diseases

Caroline A. McHutchison, Joanne Wuu, Corey T. McMillan, Rosa Rademakers, Jeffrey Statland, Gang Wu, Evadnie Rampersaud, Jason Myers, Jessica P. Hernandez, Sharon Abrahams, Michael Benatar, CReATe Consortium

Summary: In this study, researchers explored the cognitive and behavioral changes in people with motor neuron disease (MND) over time. They found that cognitive impairment was less common than previously reported and remained stable for most participants. However, a small subset of participants experienced a decline in cognition over time, which was not solely related to the C9ORF72 genetic mutation. These findings raise questions about the timing and progression of cognitive impairment in MND.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial

Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney

Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury

Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis

Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.

PARKINSONISM & RELATED DISORDERS (2023)

Article Multidisciplinary Sciences

Contributions of neighborhood social environment and air pollution exposure to Black-White disparities in epigenetic aging

Isabel Yannatos, Shana Stites, Rebecca Brown, Corey McMillan

Summary: Racial disparities in aging-related health outcomes among older Americans, known as weathering, are influenced by individual socioeconomic status, neighborhood social environment, and air pollution exposures. Black individuals have significantly accelerated DNA methylation (DNAm) aging compared to White individuals. Socioeconomic status and neighborhood deprivation contribute to the disparity in DNAm aging, while fine particulate matter exposure may also play a role for Black individuals. DNAm aging may contribute to age-related health disparities between older Black and White Americans.

PLOS ONE (2023)

No Data Available